Received Dec 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Longer than recommended interval; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 62-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose on unknown date). On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Longer than recommended interval). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 18-NOV-2025 The reporter requested data about the administration of Shingrix after the maximum interval has taken place. The reporter mentioned 4 patients, but did not have the entire data. The reporter mentioned that the first patient was a female, age 62, not specifying month and date, with no initials and they did not have any data regarding the vaccine. The batch number was not provided and a request for this information has been made.